Kailera's Obesity Pill Works. The Side Effects? Yikes.

Kailera did point to one bright spot: despite all that nausea and vomiting, very few patients actually quit the trial because of side effects. Discontinuation rates were 4.1% and 3.1% for the two active doses, barely above placebo's 2.7%. The company also noted no liver safety signals, which matters because liver toxicity has haunted other oral GLP-1 programs.

Still, there's a big difference between sticking it out in a clinical trial (where patients are motivated and monitored) and taking a pill every morning that makes you throw up two out of three days. Real-world adherence is a whole different ballgame.

Where KAI-7535 Fits in the Obesity Arms Race

The race to build a best-in-class oral obesity pill is one of the most competitive fights in pharma right now. And Kailera's results land in a crowded, unforgiving landscape.

Novo Nordisk's oral semaglutide 25 mg has posted about 13.6% weight loss in the OASIS-4 trial. Eli Lilly's orforglipron, another small-molecule GLP-1 pill, delivered roughly 11.2% in its ATTAIN-1 study. Both of those are ahead of or comparable to Kailera's 10.9%, with the critical distinction that neither has reported GI side effects anywhere near 70% nausea.

Meanwhile, injectable drugs still hold the crown. Injectable semaglutide (Wegovy) produces around 15% weight loss, and Eli Lilly's tirzepatide (Zepbound) has reached 16% to 22.5% depending on the trial. The whole pitch for oral GLP-1 drugs is convenience: no needles, just a daily pill. But that pitch only works if the pill doesn't make you miserable.

One analyst forecast projects Eli Lilly's oral pill could capture 60% of the daily oral obesity segment by 2030, versus just 21% for Novo Nordisk's oral semaglutide. Where Kailera fits into that picture is increasingly unclear.

The Kailera Backstory

Kailera isn't some scrappy startup running on fumes. The company was founded in 2024 with assets licensed from Jiangsu Hengrui Pharmaceuticals, one of China's largest drugmakers. It raised $400 million in a Series A that October, then followed up with a $600 million Series B a year later, led by Bain Capital Private Equity. Total private funding clocked in at $900 million before the company went public.

The pipeline extends beyond KAI-7535. Kailera has four clinical-stage candidates in its obesity portfolio, including an oral dual GLP-1/GIP agonist called ribupatide (KAI-9531-T) and injectable versions of the same. A global Phase 2 trial for KAI-7535 is planned, which will test the drug outside of China and provide a clearer picture of how it performs in a broader population.

What Comes Next

Kailera's Phase 3 data presents a classic biotech dilemma: the drug works, but the side effect profile needs serious improvement. The weight loss is real and clinically meaningful. The tolerability is not.

The global Phase 2 study could be a chance to refine dosing, test slower titration schedules (gradually increasing the dose to let patients adjust), or explore formulation tweaks. Those are standard plays when GI tolerability is the bottleneck. But the competition isn't waiting around.

Novo and Lilly are barreling ahead with oral pills that appear to offer similar or better efficacy with much more manageable side effects. For Kailera to carve out a meaningful share of the obesity market, its next set of data needs to answer a simple question: can you keep the weight loss and tame the nausea?

Because right now, 70% nausea isn't a side effect. It's the main effect.

BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer

BridgeBio Oncology pulled its lead KRAS drug out of the lucrative first-line lung cancer race, shrinking from a 200,000-patient opportunity to roughly 50,000. The stock dropped 24% in a single session, and the competitive fallout is just getting started.